BridgeMD
New treatment option for Hypoxia-Ischemia, Brain
Official title Early Cessation of Sedation and TTM in Patients With a Favourable EEG After Cardiac Arrest
ClinicalTrials.gov ID: NCT06048796
What this study is testing
- What it's testing
- The objective of this study is to estimate the feasibility and safety of early weaning from ICU treatment in patients after cardiac arrest and an early (\< 12 h) favourable EEG pattern (indicating no or mild postanoxic encephalopathy).
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients after cardiac arrest admitted to the ICU for treatment with sedation, TTM and mechanical ventilation.
- Age 18 years or older.
- Continuous EEG measurement started within 12 hours after cardiac arrest.
- Favourable EEG pattern within 12 hours after arrest, defined as a continuous background pattern (NVN, 2019; Ruijter et al., 2019).
- Possibility to stop sedative treatment within three hours after identification of a favourable EEG pattern.
You likely can't join if
- A known history of another medical condition with limited life expectancy (\<6 months).
- Any progressive brain illness, such as a brain tumour or neurodegenerative disease.
- Pre-admission Glasgow Outcome Scale Extended score of 4 or lower.
- Reason other than neurological condition to continue sedation and/or ventilation.
- Follow-up impossible due to logistic reasons.
See the full eligibility criteria
- Patients after cardiac arrest admitted to the ICU for treatment with sedation, TTM and mechanical ventilation.
- Age 18 years or older.
- Continuous EEG measurement started within 12 hours after cardiac arrest.
- Favourable EEG pattern within 12 hours after arrest, defined as a continuous background pattern (NVN, 2019; Ruijter et al., 2019).
- Possibility to stop sedative treatment within three hours after identification of a favourable EEG pattern.
- Written informed consent (deferred).
- A known history of another medical condition with limited life expectancy (\<6 months).
- Any progressive brain illness, such as a brain tumour or neurodegenerative disease.
- Pre-admission Glasgow Outcome Scale Extended score of 4 or lower.
- Reason other than neurological condition to continue sedation and/or ventilation.
- Follow-up impossible due to logistic reasons.
The study team makes the final eligibility decision.
Where it's taking place
- Arnhem, Gelderland, Netherlands
- Enschede, Overijssel, Netherlands
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Arnhem, Gelderland, Netherlands; Enschede, Overijssel, Netherlands. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.